Immune checkpoint inhibition in ovarian cancer - open access Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Saturday, April 16, 2016

Immune checkpoint inhibition in ovarian cancer - open access



Immune checkpoint inhibition in ovarian cancer

Navigate This Article

  1. Top
  2. Abstract
  3. Introduction
  4. The clinical significance of the local immune status in ovarian cancer
  5. The B7/CTLA-4 signal
  6. B7/CTLA-4 signal inhibitors
  7. PD-1/PD-L1 ligand signaling
  8. PD-1/PD-L1 signaling in pre-clinical cancer models
  9. PD-1/PD-L1 signaling in clinical studies of cancer
  10. Clinical applications of PD-1 inhibitors in cancer
  11. Clinical applications of PD-1 inhibitors in ovarian cancer
  12. Clinical issues related to PD-1 inhibitors for ovarian cancer
  13. Conclusions
  14. Funding
  15. Acknowledgements
  16. References 
Conclusions 
The early phase of clinical trials of immune checkpoint inhibitors for ovarian cancer have shown the manageable safety profile (17–20) and have demonstrated a dramatic durable anti-tumor response in a certain population of the patients with a 1-year schedule of nivolumab treatment, following no adjuvant anti-tumor treatment (89). Therefore, not only to explore the predictive biomarkers of responders and to find a good combination therapy but also to conduct a clinical trial to decide the maximum anti-tumor effect with a minimum treatment period of immune checkpoint inhibitors may be a next turning point to enhance the value of immune checkpoint inhibitors for ovarian cancer.  

0 comments :

Post a Comment

Your comments?